Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 15, Issue 4, 2016, Pages 373-381

  Cohen, Jeffrey A ^a   Arnold, Douglas L ^b   Comi, Giancarlo ^c   Bar Or, Amit ^b   Gujrathi, Sheila ^d   Hartung, Jeffrey P ^d   Cravets, Matt ^d   Olson, Allan ^d   Frohna, Paul A ^d   Selmaj, Krzysztof W ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d Receptos Inc   (United States)

^e Neurology Center   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GADOLINIUM; METHYLPREDNISOLONE; OZANIMOD; PLACEBO; IMMUNOLOGIC FACTOR; INDAN DERIVATIVE; OXADIAZOLE DERIVATIVE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTONOMIC DYSFUNCTION; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; COMPLETE HEART BLOCK; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; ELEVATED BLOOD PRESSURE; EUROPE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HOLTER MONITORING; HUMAN; HYPERTENSION; HYPOTENSION; INTENTION TO TREAT ANALYSIS; LYMPHOCYTE COUNT; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; ORTHOSTATIC BLOOD PRESSURE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RELAPSING MULTIPLE SCLEROSIS; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SOMATOFORM DISORDER; SQUAMOUS CELL METAPLASIA; UNITED STATES; URINARY TRACT INFECTION; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INDANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); OXADIAZOLES; RECEPTORS, LYSOSPHINGOLIPID;

EID: 84960483909     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00018-1     Document Type: Article

References (28)

1. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, 78:743-768.
2. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
3. Cohen JA, Chun J Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011, 69:759-777.
4. Calabresi PA, Radue E-W, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014, 13:545-556.
5. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
6. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
7. Forrest M, Sun SY, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004, 309:758-768.
8. Highlights of prescribing information: Gilenya (fingolimod). August, 2015 Novartis, (accessed Jan 13, 2016). https://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf.
9. Jain N, Bhatti MT Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012, 78:672-680.
10. Sun X, Singleton PA, Letsiou E, et al. Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury. Am J Respir Cell Mol Biol 2012, 47:628-636.
11. Brooks J, Peach R, Boehm M, et al. RPC1063, a selective S1P1 receptor modulator, is active in a therapeutic EAE model and exhibits favourable PK/PD properties in healthy volunteers (P915). Mult Scler J 2012, 18(suppl 4):415.
12. Peach R, Brooks J, Dedman H, Powell R, Scott F, Timony G RPC1063, a potent and selective sphingosine 1-phosphate 1 receptor modulator, has a favourable preclinical safety profile (abstract). Oct 3, 2013 (accessed Jan 13, 2016). http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=179402&XNSPRACHE_ID=2&XNKONGRESS_ID=195&XNMASKEN_ID=900.
13. Hartung J, Olson A, Peach R, et al. Absence of a relevant effect on cardiac repolarization in a QT/QTc (TQT) study of RPC1063, a novel, selective S1P1 receptor agonist, in healthy adult volunteers. Neurology 2014, 82(suppl 10):P2.229.
14. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
15. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
16. Fischer JS, Rudick RA, Cutter GR, Reingold SC The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 1999, 5:244-250. for the National MS Society Clinical Outcomes Assessment Task Force.
17. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995, 4:187-206.
18. Reboussin DM, DeMets DL, Kim KM, Lan KKG Computations for group sequential boundaries using the Lan-DeMets spending function method. Control Clin Trials 2000, 21:190-207.
19. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS. Neurology 1999, 53:466-472.
20. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
21. Noether GE Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987, 82:645-647.
22. Hartung J, Peach R, Boehm M, et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers. Oct 11, 2012 (accessed Jan 13, 2016). http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=156522&XNSPRACHE_ID=2&XNKONGRESS_ID=171&XNMASKEN_ID=900.
23. Olsson T, Boster A, Fernandez O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014, 85:1198-1208.
24. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140.
25. Kappos L, O'Connor P, Radue E-W, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 2015, 84:1582-1591.
26. Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D Experience with fingolimod in clinical practice. Int J Neurosci 2015, 125:678-685.
27. DiMarco JP, O'Connor P, Cohen JA, et al. First-dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Scler Relat Disord 2014, 3:629-638.
28. Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 2014, 54:179-188.